WeMed Medical Attended The CCPCC With DSA System And Interventional Robot
Last Friday, the 11th China Chest Pain Centers Congress （CCPCC) was held in Guangzhou. The CPCC is the highest academic platform in the field of chest pain centers in China, it aims at popularizing ideas and standardizing training, as well as making decisions and issuing standards.
WeMed Medical with its Digital Subtraction Angiography System and Interventional Robot -- ETcath appeared at the congress. Our team fully communicated and actively discussed with opinion leaders, experts, scholars, and medical staffs about the products and cooperation opportunities.
Mr. Zhai Guangyao, the associate chief physician of cardiovascular medicine at Anzhen Hospital gave a keynote speech about “The progress of interventional robot-assisted PCI treatments”. He described in detail the clinical pain points of intervention treatment and the current status of interventional surgery assistance systems, which combined with the practical application of ETcath in Anzhen Hospital. He clarified his opinions from a professional point of view about the development prospects of interventional robots and practical help to doctors.
About WeMed Medical
WeMed Medical was established in 2014, and has gradually grown from a small business to today's scale. The main business is to provide full solutions of Digital Subtraction Angiography System, Mobile DSA System, Mobile C arm X-ray Machine, and Interventional Robot. It is a hard technology enterprise with more than 100 patents, 80% of which are invention patents.
WeMed Medical adheres to the concept of "Innovation For Health", and perfectly creates a big family of "new domestic products" for intervention therapy. These new products and technologies are used in various fields such as cardiac intervention, neuro intervention, comprehensive intervention, peripheral vascular intervention, and tumor intervention.
